成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

首頁 500強(qiáng) 活動(dòng) 榜單 商業(yè) 科技 領(lǐng)導(dǎo)力 專題 品牌中心
雜志訂閱

TikTok網(wǎng)紅與“減肥神藥”

一個(gè)充斥著金錢激勵(lì)和報(bào)酬的網(wǎng)絡(luò)支撐著TikTok、YouTube和Instagram這類平臺(tái)上的大多數(shù)減肥內(nèi)容。

文本設(shè)置
小號(hào)
默認(rèn)
大號(hào)
Plus(0條)

像司美格魯肽這類GLP-1減肥藥風(fēng)靡TikTok。圖片來源:FLORIAN GAERTNER/PHOTOTHEK VIA GETTY IMAGES

TikTok上的勞倫·約翰斯頓是一位來自美國阿拉巴馬州的母親,她借助減肥藥替西帕肽(Mounjaro),在10個(gè)月的時(shí)間中從220磅(約199.58斤)減到了144磅(約130.63斤),并詳細(xì)記錄了其減肥歷程。約翰斯頓與其女兒跳舞的視頻,以及曾幾何時(shí)的訓(xùn)練緊身衣罩在她苗條身體上晃蕩不已的視頻,吸引了數(shù)十萬的點(diǎn)擊量。

在其視頻下方的評(píng)論中,觀眾分享了他們使用替西帕肽、司美格魯肽(Ozempic)、Wegovy和其他處方減肥藥的減肥歷程,并表達(dá)了希望能夠減肥成功的意愿。

一位用戶問:“你是怎么知道用它來減肥的?”

約翰斯頓用一個(gè)心形符號(hào)回復(fù)說:“點(diǎn)擊我個(gè)人資料中的鏈接,就是那個(gè)Ivim health連接?!痹撴溄佑幸粋€(gè)獨(dú)特的代碼,可以跟蹤約翰斯頓對(duì)Ivim Health的推薦。它是一家剛成立了一年半的遠(yuǎn)程醫(yī)療公司,幾乎專營像司美格魯肽和替西帕肽這樣的糖尿病藥及其化合物,并面向全美的病患開立處方和發(fā)貨。

像約翰斯頓這樣的減肥博主成為了TikTok最新的網(wǎng)紅,反映了全球?qū)LP-1(胰高血糖素樣肽-1)藥物的狂熱追捧。在TikTok搜索“司美格魯肽”便會(huì)發(fā)現(xiàn),無數(shù)此前的超重人士都在證實(shí)這款可注射藥物的療效。

其中一些網(wǎng)紅與這類藥物的銷售者之間存在著隱晦的關(guān)聯(lián)。約翰斯頓并未回復(fù)《財(cái)富》雜志有關(guān)其與Ivim關(guān)聯(lián)的問題,但對(duì)其他多位網(wǎng)紅和行業(yè)內(nèi)部人士的采訪,則揭示了一個(gè)充斥著金錢激勵(lì)和報(bào)酬的網(wǎng)絡(luò),這個(gè)網(wǎng)絡(luò)支撐著TikTok、YouTube和Instagram這類平臺(tái)上的大多數(shù)減肥內(nèi)容。

來自美國長島的母親塔拉·杰伊通過使用多種減肥藥成功減肥120磅(約108.86斤),并在這一過程中收獲了100萬的TikTok瀏覽量。她表示,每當(dāng)有人使用她的推薦鏈接來注冊Ivim,她都會(huì)拿到“近20美元”。這是很常見的事情:杰伊稱,那些開處方減肥藥的遠(yuǎn)程醫(yī)療公司每周邀請(qǐng)其合作一次。只要她推薦的人每拿到一張?zhí)幏?,公司通常都?huì)向其支付一筆費(fèi)用。杰伊表示自己并沒有這么做。

很多網(wǎng)紅都對(duì)其推廣的藥物堅(jiān)信不疑,并稱其視頻以及推薦的可開減肥藥的遠(yuǎn)程醫(yī)療公司都真心希望幫助其他人獲取這一能夠改變生活的藥物。

杰伊說:“我并不是為了錢。我真的在與這家公司合作,完全是為了幫助那些無法從其醫(yī)生或其保險(xiǎn)公司那里獲得這類藥物的人群。”

《財(cái)富》雜志采訪過的多位醫(yī)學(xué)專家表示,網(wǎng)絡(luò)紅人與遠(yuǎn)程醫(yī)療公司之間為推廣新類別的處方藥而達(dá)成了某種聯(lián)盟,我們有理由為之感到擔(dān)憂,其中大多數(shù)都是降糖藥,其減肥效用如今剛獲得美國食品與藥品監(jiān)督管理局(Food and Drug Administration)的認(rèn)可。

美國北卡羅來納大學(xué)(University of North Carolina)的吉林斯全球公共衛(wèi)生學(xué)院(Gillings School of Global Public Health)的助理副教授阿姆麗塔·鮑米克指出,美國民眾正日漸通過社交媒體來獲取健康建議,因此重要的一點(diǎn)在于,那些在市場上通過推廣這些最熱門藥物來賺錢的人是否進(jìn)行過任何披露,有沒有醫(yī)學(xué)背景或與實(shí)際的制藥公司有沒有關(guān)聯(lián)。

鮑米克稱:“遠(yuǎn)程醫(yī)療公司并不像那些擁有或制造這類藥物的公司一樣,受制于相同的監(jiān)管標(biāo)準(zhǔn)?!弊鳛椴』蓟?dòng)網(wǎng)站Health Union的首席社區(qū)官,鮑米克已經(jīng)成為了研究醫(yī)療網(wǎng)紅的專家。

互惠合作關(guān)系

生產(chǎn)司美格魯肽和替西帕肽的醫(yī)藥公司在傳統(tǒng)電視廣告上投入了重金,而網(wǎng)紅在社交媒體的營銷似乎主要由遠(yuǎn)程醫(yī)療公司主導(dǎo)。

Ivim由泰勒·坎特與安東尼·坎特兄弟于2022年4月創(chuàng)建。谷歌街景(Google Street View)顯示,這家由35名員工組成的公司將總部放在了品牌Sur la Table與品牌Kendra Scott之間的高端哥倫布商業(yè)街上。然而,盡管公司的數(shù)據(jù)沒有什么看點(diǎn),但TikTok上的標(biāo)簽#ivimhealth與#ivim各自都有著600多萬的瀏覽量,而且Ivim的首席執(zhí)行官安東尼·坎特稱,這家公司當(dāng)前與30多名網(wǎng)紅簽署了合約。

公司醫(yī)療總監(jiān)泰勒·坎特在YouTube視頻里表示:“在注冊Ivim后,人們就相當(dāng)于獲得了使用GLP-1藥物的預(yù)審核?!边@一點(diǎn)似乎與藥商的指引相違背,因?yàn)樵撝敢蟛坏孟蚧加心I臟疾病、胰腺炎或體重指數(shù)低于27的人開立司美格魯肽、Wegovy或替西帕肽。(Ivim的首席執(zhí)行官與聯(lián)合創(chuàng)始人安東尼·坎特,即泰勒·坎特的兄弟,回應(yīng)了《財(cái)富》雜志有關(guān)該視頻的詢問,并表示情況“比那個(gè)更加微妙”,同時(shí)還稱他們已經(jīng)“不止一次”更改了注冊流程。)

另一家遠(yuǎn)程醫(yī)療公司Valhalla Vitality一開始是一家迷幻劑療法提供商,治療的病癥包括創(chuàng)傷后應(yīng)激障礙。不過,公司的創(chuàng)始人及首席執(zhí)行官菲利普·達(dá)戈斯蒂諾表示,公司在一年半之后轉(zhuǎn)戰(zhàn)減肥藥領(lǐng)域。達(dá)戈斯蒂諾稱,傳統(tǒng)醫(yī)療和保險(xiǎn)通常并不能覆蓋像Valhalla這類遠(yuǎn)程醫(yī)療公司提供的療法。他說:“我的目標(biāo)只是為人們提供讓其可以掌控自身健康的工具,同時(shí)得到可信賴醫(yī)療專業(yè)人士的監(jiān)督?!?/p>

達(dá)戈斯蒂諾指出,公司與網(wǎng)紅合作是為了幫助教育公眾。他說:“我們花錢請(qǐng)博主宣傳,是因?yàn)樗麄儠?huì)在Instagram Live上直播,并帶來更多的人,然后幫助廣而告之?!背私逃娺@項(xiàng)回報(bào)之外,他表示,這家總部位于美國紐約皇后區(qū)、相對(duì)綠色的公司每月的環(huán)比增速達(dá)到了100%。

達(dá)戈斯蒂諾表示,Valhalla并不會(huì)告訴網(wǎng)紅如何去說教,但稱公司會(huì)對(duì)網(wǎng)紅發(fā)布的視頻進(jìn)行審核。他說:“我們與網(wǎng)紅簽署的唯一協(xié)議就是他們得誠實(shí),而且他們會(huì)在發(fā)布內(nèi)容之前給我們提供評(píng)審的機(jī)會(huì)?!盫alhalla支付網(wǎng)紅的方式包括現(xiàn)金(達(dá)戈斯蒂諾稱“幾小時(shí)的工作能夠賺數(shù)百美元”)或藥物折扣。

對(duì)制藥企業(yè)諾和諾德(Novo Nordisk)的司美格魯肽的需求一片欣欣向榮。圖片來源:CARSTEN SNEJBJERG/BLOOMBERG VIA GETTY IMAGES

對(duì)于居住在美國田納西州金斯波特小鎮(zhèn)的34歲的母親蕾切爾·考克斯來說,Valhalla的折扣幫了不少忙,她已經(jīng)借助替西帕肽減掉了80磅(約72.57斤)??伎怂乖赥ikTok上記錄了其減肥歷程,并借此獲得了近20萬的點(diǎn)贊和2.3萬名粉絲。她在保險(xiǎn)公司停止支付其替西帕肽處方藥費(fèi)用后,于今年早些時(shí)候與該公司開始合作。

由于替西帕肽的零售價(jià)格超過了1,000美元/月,考克斯不得不轉(zhuǎn)而使用含有替西帕肽成分的化合物(意味著她會(huì)自己在注射器中灌注含有替西帕肽成分的藥用化合物),這類化合物也不在醫(yī)保范圍之內(nèi)。為了幫助支付每瓶544美元的費(fèi)用以及她所謂的“幫助他人”,考克斯向其粉絲推薦了可以開處方藥GLP-1s和替西帕肽的Valhalla。只要有人使用考克斯的代碼注冊Valhalla的100美元的初始咨詢費(fèi)或通過該公司獲取GLP-1或替西帕肽藥物處方,她都會(huì)賺到積分,后者會(huì)轉(zhuǎn)化為其藥物的折扣。

她在談到TikTok減肥社區(qū)時(shí)表示:“感謝我的人給我發(fā)了大量的信息,因?yàn)楫?dāng)其替西帕肽被拒保之后,他們不知道去哪里獲取這類藥物?!鞭D(zhuǎn)而“分享其混合用藥歷程”收到了不俗的效果,因?yàn)樗氖鼙娡ㄟ^她發(fā)現(xiàn)了Valhalla,并將他們從互聯(lián)網(wǎng)相識(shí)轉(zhuǎn)化為“真正的好友?!?/p>

交匯于法律灰色區(qū)域的遠(yuǎn)程醫(yī)療與網(wǎng)紅

當(dāng)然,明星代言人并非是什么新事物。聯(lián)盟營銷在網(wǎng)絡(luò)紅人之間也是一種成熟的商業(yè)模式,他們會(huì)通過向賣家推薦客戶賺取傭金。不過,說到遠(yuǎn)程醫(yī)療處方藥以及網(wǎng)紅營銷,沒有明確的法規(guī)來界定哪些是合規(guī)的。

哈佛醫(yī)學(xué)院(Harvard Medical School)的生物倫理中心(Center for Bioethics)的教授阿龍·凱瑟爾海姆博士稱,在每個(gè)州,遠(yuǎn)程醫(yī)療公司補(bǔ)償網(wǎng)紅的規(guī)定各不相同,甚至各地都有自己的規(guī)定。他說:“在遠(yuǎn)程醫(yī)療公司及其操作方面,很多州的監(jiān)管措施依然處于早期階段。其中的一些關(guān)鍵問題在于,這些關(guān)系是否會(huì)被各州欺詐或自我交易法規(guī)認(rèn)定為回扣或不正當(dāng)自我交易?”

由于遠(yuǎn)程醫(yī)療公司、這類減肥藥以及網(wǎng)紅相對(duì)而言都是全新的理念,地方和聯(lián)邦監(jiān)管機(jī)構(gòu)還沒有對(duì)按推薦付費(fèi)或產(chǎn)品代言的固定費(fèi)率所得進(jìn)行區(qū)分。美國西北大學(xué)法學(xué)院(Northeastern University School of Law)的法律與媒體教授亞歷山德拉·羅伯茨表示:“不管是哪種情況,網(wǎng)紅都將發(fā)布受到贊助的內(nèi)容,因此有必要要求他們明確聲明其發(fā)布的內(nèi)容為廣告。如果他們推薦的是一款處方藥,則需要按照美國食品與藥品監(jiān)督管理局的要求提供額外的警示聲明和披露。如果所有陳述都是虛假的,具有誤導(dǎo)性,或沒有實(shí)例支撐,那么網(wǎng)紅以及聘請(qǐng)他們發(fā)布內(nèi)容或向其支付傭金的公司可能就會(huì)受到法律的制裁,這里涉及的不僅僅是美國聯(lián)邦貿(mào)易委員會(huì)(FTC)的法案,同時(shí)還有州或聯(lián)邦虛假廣告法。如果發(fā)布內(nèi)容虛假構(gòu)造與司美格魯肽生產(chǎn)公司的關(guān)聯(lián)性,此舉亦具有欺詐性?!?/p>

Ivim的首席執(zhí)行官坎特指出,使用公司推薦鏈接的網(wǎng)紅“應(yīng)該提及”其與公司的關(guān)系,“我們在協(xié)議中明確地提到了這一點(diǎn)?!盫alhalla的首席執(zhí)行官達(dá)戈斯蒂諾稱,如果他的公司發(fā)現(xiàn)某位網(wǎng)紅在其網(wǎng)絡(luò)中并沒有披露其與公司的關(guān)系,那么合約就會(huì)立即終止。(《財(cái)富》雜志發(fā)現(xiàn),盡管有些網(wǎng)紅提供了有關(guān)兩家遠(yuǎn)程醫(yī)療公司的推薦鏈接,但他們似乎沒有明確說明雙方的商業(yè)關(guān)系。)然而,哈佛醫(yī)學(xué)院生物倫理中心的凱瑟爾海姆表示,Valhalla提前審核網(wǎng)紅發(fā)布內(nèi)容的操作意味著“一定程度的營銷協(xié)調(diào),而該內(nèi)容的消費(fèi)者可能對(duì)此并不知情”。不過他指出,僅有這一點(diǎn)還不大可能構(gòu)成違法。

另一個(gè)有意思的法律問題可能涉及,遠(yuǎn)程醫(yī)療公司是否被看作連接醫(yī)療提供商與病患的科技平臺(tái)。羅伯茨在談到免除平臺(tái)發(fā)布第三方(例如網(wǎng)紅)內(nèi)容民事責(zé)任的聯(lián)邦《通信規(guī)范法案》(Communications Decency Act)章節(jié)時(shí)指出,如果是這樣的話,“第230章可能就會(huì)適用。”在眾多可能會(huì)發(fā)揮作用的變量里,最主要的是誰為網(wǎng)紅提供了其代言的產(chǎn)品,也就是減肥藥,以及網(wǎng)紅從遠(yuǎn)程醫(yī)療公司拿到的藥物折扣是否與這一決定有任何關(guān)聯(lián)。

在減肥藥風(fēng)靡市場之前,多家遠(yuǎn)程醫(yī)療公司因?yàn)槠湓诰窦膊∷幬锾幏介_立方面的操作而備受爭議。最大的遠(yuǎn)程醫(yī)療公司Cerebral在2022年成為了美國司法部(Department of Justice)調(diào)查的對(duì)象,原因在于有報(bào)道稱,公司超量開立了處方藥Xanax和Adderall。包括沃爾瑪(Walmart)和CVS在內(nèi)的藥店連鎖于2022年停止接受由專注于多動(dòng)癥的遠(yuǎn)程醫(yī)療公司Done開立的Adderall藥方。

盡管GLP-1和替西帕肽并非像Adderall和Xanax那樣屬于管制類藥物,但這些藥物相對(duì)來說都是減肥領(lǐng)域的新藥(Wegovy作為減肥藥才上市兩年的時(shí)間;司美格魯肽用于糖尿病治療才六年的時(shí)間),其長期效果和潛在的副作用依然未知。出于處方過期,以及難以承擔(dān)自費(fèi)藥物費(fèi)用的原因,很多病患停了藥,并稱自己在停藥之后的體重恢復(fù)到了原來的水平,有時(shí)甚至比服藥之前更重。

然而,這些藥物與減肥之間的關(guān)系已經(jīng)是根深蒂固,即便是美國節(jié)食療法的代言人慧儷輕體(WeightWatchers)也開始部分傾向于使用GLP-1和替西帕肽藥方。與此同時(shí),像Ro和Calibrate這樣在新冠疫情期間成為了風(fēng)投資本和消費(fèi)者心頭好的遠(yuǎn)程醫(yī)療機(jī)構(gòu),也推出了滿足減肥需求的項(xiàng)目。與新冠疫情期間居家購藥需求一樣,GLP-1藥物熱已經(jīng)促使多家新公司加入減肥藥陣營,包括Ivim、Slym、bmiMD、Push Health、Sunrise、Mochi Health、Accomplish Health等等。

Ivim的首席執(zhí)行官坎特稱,公司的目標(biāo)不僅僅是為病患提供藥物,同時(shí)還將提供教育以及諸如健康指導(dǎo)這樣的資源獲取渠道。

歡迎加入GLP-1的“密友派對(duì)”

對(duì)于很多減肥網(wǎng)紅而言,TikTok視頻基本上就是對(duì)其自身正面經(jīng)驗(yàn)的證詞,而且也是為面臨減肥困境的其他人提供了社區(qū)和支持。

今年10月,Ivim的網(wǎng)紅蕾切爾·奈特·格萊特,又名LoveNestConversation,稱已經(jīng)在兩年半減了146磅(約132.45斤),她將為減肥藥社區(qū)舉行一場“大納什維爾GLP1密友派對(duì)”(Big Nashville GLP1 Bestie Bash)。

“在精彩絕倫的周末派對(duì)上,能夠相互會(huì)面,分享我們的成功故事,為我們的GLP1大家庭加油打氣,并結(jié)交新朋友?!?/p>

蔡斯·弗蘭克斯是一位擁有專業(yè)資格證的護(hù)士,她通過在TikTok上發(fā)布有關(guān)GLP-1藥物的內(nèi)容收獲了超過8.5萬名粉絲。對(duì)他來說,TikTok上的減肥人群成為了其部落,因?yàn)樗麄兘?jīng)常會(huì)在其視頻下組織評(píng)論。擔(dān)任Ivim顧問的弗蘭克斯說:“TikTok上的GLP-1群體真的吸納了一群在社會(huì)上受到不公平待遇的人群,比如遭遇肥胖恐懼癥、體重歧視等。他們就像是一個(gè)支持小組?!?/p>

他說:“如果查看我視頻或創(chuàng)作欄的評(píng)論,你就會(huì)發(fā)現(xiàn)人們在相互打氣,并鼓勵(lì)大家接受和欣賞自己的身體。”(財(cái)富中文網(wǎng))

譯者:馮豐

審校:夏林

TikTok上的勞倫·約翰斯頓是一位來自美國阿拉巴馬州的母親,她借助減肥藥替西帕肽(Mounjaro),在10個(gè)月的時(shí)間中從220磅(約199.58斤)減到了144磅(約130.63斤),并詳細(xì)記錄了其減肥歷程。約翰斯頓與其女兒跳舞的視頻,以及曾幾何時(shí)的訓(xùn)練緊身衣罩在她苗條身體上晃蕩不已的視頻,吸引了數(shù)十萬的點(diǎn)擊量。

在其視頻下方的評(píng)論中,觀眾分享了他們使用替西帕肽、司美格魯肽(Ozempic)、Wegovy和其他處方減肥藥的減肥歷程,并表達(dá)了希望能夠減肥成功的意愿。

一位用戶問:“你是怎么知道用它來減肥的?”

約翰斯頓用一個(gè)心形符號(hào)回復(fù)說:“點(diǎn)擊我個(gè)人資料中的鏈接,就是那個(gè)Ivim health連接?!痹撴溄佑幸粋€(gè)獨(dú)特的代碼,可以跟蹤約翰斯頓對(duì)Ivim Health的推薦。它是一家剛成立了一年半的遠(yuǎn)程醫(yī)療公司,幾乎專營像司美格魯肽和替西帕肽這樣的糖尿病藥及其化合物,并面向全美的病患開立處方和發(fā)貨。

像約翰斯頓這樣的減肥博主成為了TikTok最新的網(wǎng)紅,反映了全球?qū)LP-1(胰高血糖素樣肽-1)藥物的狂熱追捧。在TikTok搜索“司美格魯肽”便會(huì)發(fā)現(xiàn),無數(shù)此前的超重人士都在證實(shí)這款可注射藥物的療效。

其中一些網(wǎng)紅與這類藥物的銷售者之間存在著隱晦的關(guān)聯(lián)。約翰斯頓并未回復(fù)《財(cái)富》雜志有關(guān)其與Ivim關(guān)聯(lián)的問題,但對(duì)其他多位網(wǎng)紅和行業(yè)內(nèi)部人士的采訪,則揭示了一個(gè)充斥著金錢激勵(lì)和報(bào)酬的網(wǎng)絡(luò),這個(gè)網(wǎng)絡(luò)支撐著TikTok、YouTube和Instagram這類平臺(tái)上的大多數(shù)減肥內(nèi)容。

來自美國長島的母親塔拉·杰伊通過使用多種減肥藥成功減肥120磅(約108.86斤),并在這一過程中收獲了100萬的TikTok瀏覽量。她表示,每當(dāng)有人使用她的推薦鏈接來注冊Ivim,她都會(huì)拿到“近20美元”。這是很常見的事情:杰伊稱,那些開處方減肥藥的遠(yuǎn)程醫(yī)療公司每周邀請(qǐng)其合作一次。只要她推薦的人每拿到一張?zhí)幏?,公司通常都?huì)向其支付一筆費(fèi)用。杰伊表示自己并沒有這么做。

很多網(wǎng)紅都對(duì)其推廣的藥物堅(jiān)信不疑,并稱其視頻以及推薦的可開減肥藥的遠(yuǎn)程醫(yī)療公司都真心希望幫助其他人獲取這一能夠改變生活的藥物。

杰伊說:“我并不是為了錢。我真的在與這家公司合作,完全是為了幫助那些無法從其醫(yī)生或其保險(xiǎn)公司那里獲得這類藥物的人群。”

《財(cái)富》雜志采訪過的多位醫(yī)學(xué)專家表示,網(wǎng)絡(luò)紅人與遠(yuǎn)程醫(yī)療公司之間為推廣新類別的處方藥而達(dá)成了某種聯(lián)盟,我們有理由為之感到擔(dān)憂,其中大多數(shù)都是降糖藥,其減肥效用如今剛獲得美國食品與藥品監(jiān)督管理局(Food and Drug Administration)的認(rèn)可。

美國北卡羅來納大學(xué)(University of North Carolina)的吉林斯全球公共衛(wèi)生學(xué)院(Gillings School of Global Public Health)的助理副教授阿姆麗塔·鮑米克指出,美國民眾正日漸通過社交媒體來獲取健康建議,因此重要的一點(diǎn)在于,那些在市場上通過推廣這些最熱門藥物來賺錢的人是否進(jìn)行過任何披露,有沒有醫(yī)學(xué)背景或與實(shí)際的制藥公司有沒有關(guān)聯(lián)。

鮑米克稱:“遠(yuǎn)程醫(yī)療公司并不像那些擁有或制造這類藥物的公司一樣,受制于相同的監(jiān)管標(biāo)準(zhǔn)。”作為病患互動(dòng)網(wǎng)站Health Union的首席社區(qū)官,鮑米克已經(jīng)成為了研究醫(yī)療網(wǎng)紅的專家。

互惠合作關(guān)系

生產(chǎn)司美格魯肽和替西帕肽的醫(yī)藥公司在傳統(tǒng)電視廣告上投入了重金,而網(wǎng)紅在社交媒體的營銷似乎主要由遠(yuǎn)程醫(yī)療公司主導(dǎo)。

Ivim由泰勒·坎特與安東尼·坎特兄弟于2022年4月創(chuàng)建。谷歌街景(Google Street View)顯示,這家由35名員工組成的公司將總部放在了品牌Sur la Table與品牌Kendra Scott之間的高端哥倫布商業(yè)街上。然而,盡管公司的數(shù)據(jù)沒有什么看點(diǎn),但TikTok上的標(biāo)簽#ivimhealth與#ivim各自都有著600多萬的瀏覽量,而且Ivim的首席執(zhí)行官安東尼·坎特稱,這家公司當(dāng)前與30多名網(wǎng)紅簽署了合約。

公司醫(yī)療總監(jiān)泰勒·坎特在YouTube視頻里表示:“在注冊Ivim后,人們就相當(dāng)于獲得了使用GLP-1藥物的預(yù)審核。”這一點(diǎn)似乎與藥商的指引相違背,因?yàn)樵撝敢蟛坏孟蚧加心I臟疾病、胰腺炎或體重指數(shù)低于27的人開立司美格魯肽、Wegovy或替西帕肽。(Ivim的首席執(zhí)行官與聯(lián)合創(chuàng)始人安東尼·坎特,即泰勒·坎特的兄弟,回應(yīng)了《財(cái)富》雜志有關(guān)該視頻的詢問,并表示情況“比那個(gè)更加微妙”,同時(shí)還稱他們已經(jīng)“不止一次”更改了注冊流程。)

另一家遠(yuǎn)程醫(yī)療公司Valhalla Vitality一開始是一家迷幻劑療法提供商,治療的病癥包括創(chuàng)傷后應(yīng)激障礙。不過,公司的創(chuàng)始人及首席執(zhí)行官菲利普·達(dá)戈斯蒂諾表示,公司在一年半之后轉(zhuǎn)戰(zhàn)減肥藥領(lǐng)域。達(dá)戈斯蒂諾稱,傳統(tǒng)醫(yī)療和保險(xiǎn)通常并不能覆蓋像Valhalla這類遠(yuǎn)程醫(yī)療公司提供的療法。他說:“我的目標(biāo)只是為人們提供讓其可以掌控自身健康的工具,同時(shí)得到可信賴醫(yī)療專業(yè)人士的監(jiān)督。”

達(dá)戈斯蒂諾指出,公司與網(wǎng)紅合作是為了幫助教育公眾。他說:“我們花錢請(qǐng)博主宣傳,是因?yàn)樗麄儠?huì)在Instagram Live上直播,并帶來更多的人,然后幫助廣而告之。”除了教育公眾這項(xiàng)回報(bào)之外,他表示,這家總部位于美國紐約皇后區(qū)、相對(duì)綠色的公司每月的環(huán)比增速達(dá)到了100%。

達(dá)戈斯蒂諾表示,Valhalla并不會(huì)告訴網(wǎng)紅如何去說教,但稱公司會(huì)對(duì)網(wǎng)紅發(fā)布的視頻進(jìn)行審核。他說:“我們與網(wǎng)紅簽署的唯一協(xié)議就是他們得誠實(shí),而且他們會(huì)在發(fā)布內(nèi)容之前給我們提供評(píng)審的機(jī)會(huì)?!盫alhalla支付網(wǎng)紅的方式包括現(xiàn)金(達(dá)戈斯蒂諾稱“幾小時(shí)的工作能夠賺數(shù)百美元”)或藥物折扣。

對(duì)于居住在美國田納西州金斯波特小鎮(zhèn)的34歲的母親蕾切爾·考克斯來說,Valhalla的折扣幫了不少忙,她已經(jīng)借助替西帕肽減掉了80磅(約72.57斤)。考克斯在TikTok上記錄了其減肥歷程,并借此獲得了近20萬的點(diǎn)贊和2.3萬名粉絲。她在保險(xiǎn)公司停止支付其替西帕肽處方藥費(fèi)用后,于今年早些時(shí)候與該公司開始合作。

由于替西帕肽的零售價(jià)格超過了1,000美元/月,考克斯不得不轉(zhuǎn)而使用含有替西帕肽成分的化合物(意味著她會(huì)自己在注射器中灌注含有替西帕肽成分的藥用化合物),這類化合物也不在醫(yī)保范圍之內(nèi)。為了幫助支付每瓶544美元的費(fèi)用以及她所謂的“幫助他人”,考克斯向其粉絲推薦了可以開處方藥GLP-1s和替西帕肽的Valhalla。只要有人使用考克斯的代碼注冊Valhalla的100美元的初始咨詢費(fèi)或通過該公司獲取GLP-1或替西帕肽藥物處方,她都會(huì)賺到積分,后者會(huì)轉(zhuǎn)化為其藥物的折扣。

她在談到TikTok減肥社區(qū)時(shí)表示:“感謝我的人給我發(fā)了大量的信息,因?yàn)楫?dāng)其替西帕肽被拒保之后,他們不知道去哪里獲取這類藥物?!鞭D(zhuǎn)而“分享其混合用藥歷程”收到了不俗的效果,因?yàn)樗氖鼙娡ㄟ^她發(fā)現(xiàn)了Valhalla,并將他們從互聯(lián)網(wǎng)相識(shí)轉(zhuǎn)化為“真正的好友?!?/p>

交匯于法律灰色區(qū)域的遠(yuǎn)程醫(yī)療與網(wǎng)紅

當(dāng)然,明星代言人并非是什么新事物。聯(lián)盟營銷在網(wǎng)絡(luò)紅人之間也是一種成熟的商業(yè)模式,他們會(huì)通過向賣家推薦客戶賺取傭金。不過,說到遠(yuǎn)程醫(yī)療處方藥以及網(wǎng)紅營銷,沒有明確的法規(guī)來界定哪些是合規(guī)的。

哈佛醫(yī)學(xué)院(Harvard Medical School)的生物倫理中心(Center for Bioethics)的教授阿龍·凱瑟爾海姆博士稱,在每個(gè)州,遠(yuǎn)程醫(yī)療公司補(bǔ)償網(wǎng)紅的規(guī)定各不相同,甚至各地都有自己的規(guī)定。他說:“在遠(yuǎn)程醫(yī)療公司及其操作方面,很多州的監(jiān)管措施依然處于早期階段。其中的一些關(guān)鍵問題在于,這些關(guān)系是否會(huì)被各州欺詐或自我交易法規(guī)認(rèn)定為回扣或不正當(dāng)自我交易?”

由于遠(yuǎn)程醫(yī)療公司、這類減肥藥以及網(wǎng)紅相對(duì)而言都是全新的理念,地方和聯(lián)邦監(jiān)管機(jī)構(gòu)還沒有對(duì)按推薦付費(fèi)或產(chǎn)品代言的固定費(fèi)率所得進(jìn)行區(qū)分。美國西北大學(xué)法學(xué)院(Northeastern University School of Law)的法律與媒體教授亞歷山德拉·羅伯茨表示:“不管是哪種情況,網(wǎng)紅都將發(fā)布受到贊助的內(nèi)容,因此有必要要求他們明確聲明其發(fā)布的內(nèi)容為廣告。如果他們推薦的是一款處方藥,則需要按照美國食品與藥品監(jiān)督管理局的要求提供額外的警示聲明和披露。如果所有陳述都是虛假的,具有誤導(dǎo)性,或沒有實(shí)例支撐,那么網(wǎng)紅以及聘請(qǐng)他們發(fā)布內(nèi)容或向其支付傭金的公司可能就會(huì)受到法律的制裁,這里涉及的不僅僅是美國聯(lián)邦貿(mào)易委員會(huì)(FTC)的法案,同時(shí)還有州或聯(lián)邦虛假廣告法。如果發(fā)布內(nèi)容虛假構(gòu)造與司美格魯肽生產(chǎn)公司的關(guān)聯(lián)性,此舉亦具有欺詐性。”

Ivim的首席執(zhí)行官坎特指出,使用公司推薦鏈接的網(wǎng)紅“應(yīng)該提及”其與公司的關(guān)系,“我們在協(xié)議中明確地提到了這一點(diǎn)。”Valhalla的首席執(zhí)行官達(dá)戈斯蒂諾稱,如果他的公司發(fā)現(xiàn)某位網(wǎng)紅在其網(wǎng)絡(luò)中并沒有披露其與公司的關(guān)系,那么合約就會(huì)立即終止。(《財(cái)富》雜志發(fā)現(xiàn),盡管有些網(wǎng)紅提供了有關(guān)兩家遠(yuǎn)程醫(yī)療公司的推薦鏈接,但他們似乎沒有明確說明雙方的商業(yè)關(guān)系。)然而,哈佛醫(yī)學(xué)院生物倫理中心的凱瑟爾海姆表示,Valhalla提前審核網(wǎng)紅發(fā)布內(nèi)容的操作意味著“一定程度的營銷協(xié)調(diào),而該內(nèi)容的消費(fèi)者可能對(duì)此并不知情”。不過他指出,僅有這一點(diǎn)還不大可能構(gòu)成違法。

另一個(gè)有意思的法律問題可能涉及,遠(yuǎn)程醫(yī)療公司是否被看作連接醫(yī)療提供商與病患的科技平臺(tái)。羅伯茨在談到免除平臺(tái)發(fā)布第三方(例如網(wǎng)紅)內(nèi)容民事責(zé)任的聯(lián)邦《通信規(guī)范法案》(Communications Decency Act)章節(jié)時(shí)指出,如果是這樣的話,“第230章可能就會(huì)適用?!痹诒姸嗫赡軙?huì)發(fā)揮作用的變量里,最主要的是誰為網(wǎng)紅提供了其代言的產(chǎn)品,也就是減肥藥,以及網(wǎng)紅從遠(yuǎn)程醫(yī)療公司拿到的藥物折扣是否與這一決定有任何關(guān)聯(lián)。

在減肥藥風(fēng)靡市場之前,多家遠(yuǎn)程醫(yī)療公司因?yàn)槠湓诰窦膊∷幬锾幏介_立方面的操作而備受爭議。最大的遠(yuǎn)程醫(yī)療公司Cerebral在2022年成為了美國司法部(Department of Justice)調(diào)查的對(duì)象,原因在于有報(bào)道稱,公司超量開立了處方藥Xanax和Adderall。包括沃爾瑪(Walmart)和CVS在內(nèi)的藥店連鎖于2022年停止接受由專注于多動(dòng)癥的遠(yuǎn)程醫(yī)療公司Done開立的Adderall藥方。

盡管GLP-1和替西帕肽并非像Adderall和Xanax那樣屬于管制類藥物,但這些藥物相對(duì)來說都是減肥領(lǐng)域的新藥(Wegovy作為減肥藥才上市兩年的時(shí)間;司美格魯肽用于糖尿病治療才六年的時(shí)間),其長期效果和潛在的副作用依然未知。出于處方過期,以及難以承擔(dān)自費(fèi)藥物費(fèi)用的原因,很多病患停了藥,并稱自己在停藥之后的體重恢復(fù)到了原來的水平,有時(shí)甚至比服藥之前更重。

然而,這些藥物與減肥之間的關(guān)系已經(jīng)是根深蒂固,即便是美國節(jié)食療法的代言人慧儷輕體(WeightWatchers)也開始部分傾向于使用GLP-1和替西帕肽藥方。與此同時(shí),像Ro和Calibrate這樣在新冠疫情期間成為了風(fēng)投資本和消費(fèi)者心頭好的遠(yuǎn)程醫(yī)療機(jī)構(gòu),也推出了滿足減肥需求的項(xiàng)目。與新冠疫情期間居家購藥需求一樣,GLP-1藥物熱已經(jīng)促使多家新公司加入減肥藥陣營,包括Ivim、Slym、bmiMD、Push Health、Sunrise、Mochi Health、Accomplish Health等等。

Ivim的首席執(zhí)行官坎特稱,公司的目標(biāo)不僅僅是為病患提供藥物,同時(shí)還將提供教育以及諸如健康指導(dǎo)這樣的資源獲取渠道。

歡迎加入GLP-1的“密友派對(duì)”

對(duì)于很多減肥網(wǎng)紅而言,TikTok視頻基本上就是對(duì)其自身正面經(jīng)驗(yàn)的證詞,而且也是為面臨減肥困境的其他人提供了社區(qū)和支持。

今年10月,Ivim的網(wǎng)紅蕾切爾·奈特·格萊特,又名LoveNestConversation,稱已經(jīng)在兩年半減了146磅(約132.45斤),她將為減肥藥社區(qū)舉行一場“大納什維爾GLP1密友派對(duì)”(Big Nashville GLP1 Bestie Bash)。

“在精彩絕倫的周末派對(duì)上,能夠相互會(huì)面,分享我們的成功故事,為我們的GLP1大家庭加油打氣,并結(jié)交新朋友?!?/p>

蔡斯·弗蘭克斯是一位擁有專業(yè)資格證的護(hù)士,她通過在TikTok上發(fā)布有關(guān)GLP-1藥物的內(nèi)容收獲了超過8.5萬名粉絲。對(duì)他來說,TikTok上的減肥人群成為了其部落,因?yàn)樗麄兘?jīng)常會(huì)在其視頻下組織評(píng)論。擔(dān)任Ivim顧問的弗蘭克斯說:“TikTok上的GLP-1群體真的吸納了一群在社會(huì)上受到不公平待遇的人群,比如遭遇肥胖恐懼癥、體重歧視等。他們就像是一個(gè)支持小組?!?/p>

他說:“如果查看我視頻或創(chuàng)作欄的評(píng)論,你就會(huì)發(fā)現(xiàn)人們在相互打氣,并鼓勵(lì)大家接受和欣賞自己的身體?!保ㄘ?cái)富中文網(wǎng))

譯者:馮豐

審校:夏林

Lauren Johnston is an Alabama mom on TikTok who has dutifully documented her 10-month journey from 220 pounds to 144 pounds using weight loss drug Mounjaro. The videos of Johnston dancing with her daughter, and of the once skintight workout tops transformed into billowy neon fabrics hanging from her petite frame, have garnered hundreds of thousands of views.

In the comments under the videos, viewers share their own tales of pound shedding with Mounjaro, Ozempic, Wegovy, and other prescription weight loss drugs, and express their desire to emulate her success.

“How’d you get started on it?” asks one user.

“Click the link in my bio it’s the Ivim health one,” Johnston writes back with a heart emoji. This link has a unique code to track Johnston’s referrals to Ivim Health, a one-and-a-half-year-old telehealth company that deals almost exclusively in antidiabetic drugs like Ozempic and Mounjaro and their compounds, prescribing and shipping the medications to patients around the country.

Weight loss influencers like Johnston are the latest sensation on TikTok, reflecting a worldwide craze for the so-called GLP-1 (glucagon-like peptide-1) drugs. Search for “Ozempic” on TikTok and you’ll find an endless feed of formerly obese people attesting to the efficacy of the injectable medications.

What’s less readily apparent are the relationships between some of these influencers and the dispensers of the medications. Johnson did not respond to Fortune’s queries about her relationship with Ivim, but interviews with several other influencers and industry insiders, including the CEO of Ivim, revealed a web of financial incentives and payments underpinning much of the weight loss content on platforms like TikTok, YouTube, and Instagram.

Tara Jay, a Long Island mom who lost 120 pounds on a combination of weight loss medications and picked up 1 million TikTok views in the process, says she gets paid an amount that’s “l(fā)ess than $20” every time someone uses her referral link to register with Ivim. And it’s hardly unusual: Jay says that telehealth companies that prescribe weight loss drugs solicit her for partnerships about once per week, often offering to pay her a fee each time one of her referrals gets a prescription, something Jay says she doesn’t do.

Many of the influencers swear by the drugs they’re promoting, and say their videos and referrals to telehealth companies that can prescribe are born out of a genuine desire to help others get access to a life-changing drug.

“I’m not doing this for money. I really got involved with this company to absolutely help people who just weren’t able to get it from their doctors’ or their insurance,” says Jay.

But several medical experts that Fortune spoke to say there’s reason to be cautious about the alliance between internet influencers and telehealth companies in promoting the new class of prescription drugs, most of which are technically anti-diabetes drugs whose weight loss benefits are just now being recognized by the Food and Drug Administration.

Americans increasingly turn to social media for health advice, so it matters if those pushing the hottest drugs on the market are profiting without any disclosures, medical backgrounds or relationships with the actual pharmaceutical companies, says Amrita Bhowmick, an adjunct assistant professor at the University of North Carolina’s Gillings School of Global Public Health.

“Telehealth companies are not held to the same regulatory standards as a pharmaceutical company that owns or manufactures that drug,” says Bhomwick, who has become an expert on healthcare influencers as the chief community officer of patient-to-patient connection website Health Union.

A mutually beneficial partnership

While the pharmaceutical companies that produce Ozempic and Mounjaro spend hefty sums of money on traditional TV ads, the influencer marketing on social media appears to be primarily led by telehealth companies.

Ivim was incorporated in April 2022 by brothers Taylor and Anthony Kantor. The 35-person company lists headquarters in a high-end Columbus strip mall between Sur la Table and Kendra Scott, according to Google Street View. But despite these low-key corporate data points, on TikTok the hashtags #ivimhealth and #ivim each have over 6 million views and Ivim CEO Anthony Kantor notes that the company has concurrent contracts with over 30 influencers.

“By registering with Ivim, you have already been preapproved for a GLP-1 medication,” says the company’s medical director Taylor Kantor in a YouTube video, which appears to contradict the guidance of the drugmakers that individuals with kidney problems, pancreatitis or a body mass index lower than 27 should not be prescribed Ozempic, Wegovy or Mounjaro. (Ivim CEO and cofounder Anthony Kantor, who also is Taylor Kantor’s brother, responded to Fortune’s query about the video, and said that it’s “a bit more nuanced than that,” adding that they’ve changed the registration process “quite a few times.”)

Valhalla Vitality, another telehealth company, began as a purveyor of psychedelic treatments for conditions, including post-traumatic stress disorder, but moved into weight loss drugs a year and a half ago, according to founder and CEO Philip D’Agostino. Conventional medical care and insurance often don’t cover the kind of treatments that telehealth companies like Valhalla provide, D’Agostino says. “My whole goal for this was to give people the access to the tools that they need to control their health in their own hands—with the supervision of a trusted medical professional,” he says.

D’Agostino said the company works with influencers to help educate the public. “If we’re paying somebody, it’s because it’s somebody who’s going to go on Instagram Live and bring in other people and help educate a larger group,” he said. And he’s gotten more than an education, noting that revenues consistently grow 100% month-over-month for the relatively green Queens, N.Y.–based company.

He said Valhalla doesn’t tell influencers what to say, but noted that the company approves the videos that the influencers post. “The only agreements that we have with our influencers is that they’re honest, and that they give us a chance to review it before they post,” he says. Valhalla’s payments to influencers can range from cash—which D’Agostino described as a “couple hundred dollars for a couple of hours’ work”—to discounts on medication.

For Rachel Cox, a 34-year-old mom based in small-town Kingsport, Tenn., who shed 80 pounds on Mounjaro, Valhalla’s discounts have been helpful. Cox, who amassed nearly 200,000 likes and 23,000 followers on TikTok by chronicling her weight loss journey, partnered with the company earlier this year after insurance stopped covering her Mounjaro prescription.

Because Mounjaro retails for over $1,000 per month out of pocket, Cox had to switch over to a compound version of tirzepatide (meaning that she fills the syringes herself with pharmaceutical compounds that constitute a tirzepatide), which also falls outside of insurance coverage. To help cover payments of $544 per vial and, in her words, “help people,” Cox refers her followers to Valhalla, which prescribes compound GLP-1s and tirzepatides. Every time someone uses Cox’s code to register for Valhalla’s $100 initial consultation or gets a GLP-1 or tirzepatide compound prescription through the company, she earns points, which translate to discounts on her medications.

“I get a lot of messages from people thanking me, because when their Mounjaro was declined [by insurance coverage], they didn’t know where to go,” she says of the weight loss TikTok community. Switching to “sharing [her] compounded journey” has been “amazing” because her audience has found Valhalla through her content, transforming them from internet acquaintances to “true friends.”

The legal gray area where telehealths and influencers meet

Celebrity spokespeople are nothing new, of course. And affiliate marketing is a well-established business model among internet influencers, who earn commissions from sellers for referring customers. When it comes to telehealth prescriptions and influencer marketing, though, the rules around what’s acceptable are not so clear-cut.

Dr. Aaron Kesselheim, a professor at Harvard Medical School’s Center for Bioethics, says the rules around how telehealth companies compensate influencers could vary on a state-by-state basis, and even be determined at a local level. “A lot of state regulatory practices with respect to telehealth companies and their practices are still in the early stages,” he says. “Would these relationships be considered kickbacks or improper self-dealing under state fraud or self-dealing statutes should be some of the key questions,” he said.

Because telehealth, this class of weight loss drugs, and influencers are all relatively novel concepts, local and federal regulators have not differentiated between payments based on referrals or flat fees for endorsing a product. “In either case, the influencer is posting sponsored content and is required to disclose clearly and conspicuously that their posts are ads. If they’re advertising a prescription drug, additional warnings and disclosures are likely to be required by the FDA,” says Alexandra Roberts, a professor of law and media at Northeastern University School of Law. “If any representations are false, misleading, or unsubstantiated, both the influencer and the company that is paying them to post or paying them commission may be liable under not just FTC law, but also state or federal false advertising law. And if the posts falsely create the perception of affiliation with the company that makes Ozempic, that can be deceptive too.”

Ivim’s CEO Kantor says influencers who use the firm’s referral links “should be mentioning” their relationship with the company—”we definitely tell them that in our agreement.” D’Agostino, the Valhalla CEO, said that if his company discovers that an influencer in its network is not disclosing their relationship with the company, their contract is immediately terminated. (Fortune found influencers with referral links to both telehealth companies who did not appear to have clear disclosures of their commercial relationships.) Still, Valhalla’s practice of reviewing influencer posts beforehand suggests “a level of marketing coordination that consumers of the content probably aren’t aware of,” said Kessselheim, of Harvard Medical School’s Center for Bioethics, though he noted that alone was unlikely to be illegal.

An interesting legal wrinkle could also involve whether a telehealth firm is considered a technology platform that connects medical providers to patients. In that case, “Section 230 might come into play,” says Roberts, referring to the section of the federal Communications Decency Act that shields platforms from civil liability for content posted by third-parties (for example, influencers). Among the many variables that could come into play are the details about who provided the influencer with the product they endorsed—in this case weight loss drugs—and if the discounts on medication that an influencer received from a telehealth have any bearing on that determination.

The mania for weight loss drugs comes shortly after several telehealth companies became embroiled in controversies over their prescription practices for drugs to treat mental health issues. Cerebral, one of the largest telehealth companies, became the subject of a Department of Justice investigation in 2022 following reports that it overprescribed Xanax and Adderall. Pharmacy chains including Walmart and CVS stopped filling Adderall prescriptions from ADHD-focused telehealth Done in 2022.

While GLP-1 and tirzepatides are not controlled substances like Adderall and Xanax, the drugs are considered relatively novel for weight loss (Wegovy has been on the market for just two years as a weight loss drug; Ozempic for about six to treat diabetes), and their long-term effects and potential adverse effects are still unknown. Many patients report that after they stopped taking the drugs—often because their prescriptions expired and they could not afford to pay out of pocket—they gained back the weight, sometimes getting heavier than they were prior to starting on the medications.

Still, the drugs have become so associated with weight loss that even WeightWatchers, synonymous with American dieting, has in-part pivoted to GLP-1 and tirzepatide prescriptions. Meanwhile telehealths like Ro and Calibrate that became VC and consumer darlings during COVID-19 have launched programs to meet weight loss demands. And just like the demand for medicine from home during the pandemic, the GLP-1 fever has spawned a slew of new companies designed to dose: Ivim, Slym, bmiMD, Push Health, Sunrise, Mochi Health, Accomplish Health, and many more.

Kantor, the CEO of Ivim, says the company’s goal is to provide patients not just medication, but education and access to resources like health coaches.

Welcome to the GLP-1 “Bestie Bash”

For many weight loss influencers, the TikTok videos are most of all a testament to their own positive experiences, and a way to provide community and support for others who have faced similar struggles to get slim.

This October, Ivim influencer Rachael Knight Gullette, who goes by LoveNestConversation and claims to have lost 146 pounds in two and a half years, is hosting a meetup for the prescription weight loss community called the Big Nashville GLP1 Bestie Bash.

The goals: “the most amazing weekend of meeting each other in person, sharing our success stories, providing encouragement to our fellow GLP1 family, and making new friends.”

Chace Franks is a board-certified nurse practitioner who has garnered over 85,000 followers posting about GLP-1s on TikTok. For him, the people of weight loss TikTok have become his tribe as they often organize in the comments of his videos. “The GLP-1 community on Tiktok has really banded together a portion of society that has been treated unfairly—whether it’s fatphobia, weight bias, things like that; it’s like a support group, almost,” says Franks, who is an adviser for Ivim.

“If you look at the comments on my videos or creators’,” he says, “it’s people hyping people up—it’s promoting body positivity.”

財(cái)富中文網(wǎng)所刊載內(nèi)容之知識(shí)產(chǎn)權(quán)為財(cái)富媒體知識(shí)產(chǎn)權(quán)有限公司及/或相關(guān)權(quán)利人專屬所有或持有。未經(jīng)許可,禁止進(jìn)行轉(zhuǎn)載、摘編、復(fù)制及建立鏡像等任何使用。
0條Plus
精彩評(píng)論
評(píng)論

撰寫或查看更多評(píng)論

請(qǐng)打開財(cái)富Plus APP

前往打開
熱讀文章
无码一区二区三区免费| 丁香婷婷在线成人播放视频| 欧美日韩精品高清一区二区| 日产无人区一线二线三线观看| 国产成人无码精品久久久露脸| 亚洲精品无码久久久久久久| 美女视频一区二区三区在线教室内污辱女教师在线播放| 亚洲无人区午夜福利码高清完整版 | 亚洲av无码无限在线观看| 麻豆蜜桃国产精品无码视频| 在线观看你懂的国产精品| 国产成人精品亚洲日本专区61| 无码少妇A片一区二区三区| 99久久精品国产综合一区| 人妻大战黑人白浆狂泄| 日韩精品无码专区| 国产精品无码A∨精品影院| 成人AV鲁丝片一区二区免费| 日韩无码精品一区二区三区| 亚洲Av无码乱码在线观看| 日韩免费无码视频一区二区三区| 精品无人区无码乱码毛片国产| 日韩国产欧美二区高清| 亚洲VA欧美va国产va综合| 亚洲av无码专区国产乱码4se| 久久精品国产99国产精2020| 制服丝祙女教师在线播放| 亚洲高清在不卡一区二区三区| 免费人成视频在线观看| 日韩不卡一区二区三区| 国产福利一区二区三区高清| 人人人澡人人人妻人人人精品| 久久99亚洲网美利坚合众国| 久久AV无码精品人妻出轨| 国产精品亚洲片夜色在线| 国产成人一区二区三区视频免费| 欧美日韩精品一区二区免费高清| 国产精品天天看特色大片互動交流| 97久久精品无码一区二区天美| 华人色视频在线观看| 国产午夜亚洲精品一级在线|